Neuland Laboratories Limited (NEULANDLAB.BO)
INR 11201.8
(2.31%)
INR 11201.8
(2.31%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 5.49 Billion INR | -6.11% |
| 2022 | 5.85 Billion INR | 7.86% |
| 2021 | 5.42 Billion INR | 0.87% |
| 2020 | 5.38 Billion INR | 3.32% |
| 2019 | 5.21 Billion INR | 20.87% |
| 2018 | 4.31 Billion INR | -16.03% |
| 2017 | 5.13 Billion INR | 51.0% |
| 2016 | 3.39 Billion INR | 7.27% |
| 2015 | 3.16 Billion INR | -9.43% |
| 2014 | 3.49 Billion INR | -2.6% |
| 2013 | 3.59 Billion INR | 10.48% |
| 2012 | 3.25 Billion INR | -6.91% |
| 2011 | 3.49 Billion INR | -1.32% |
| 2010 | 3.53 Billion INR | 7.47% |
| 2009 | 3.29 Billion INR | 10.61% |
| 2008 | 2.97 Billion INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | -12.82 Billion INR | -333.28% |
| 2023 Q4 | 5.49 Billion INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 FY | 5.49 Billion INR | -6.11% |
| 2023 Q2 | 5.32 Billion INR | 0.0% |
| 2022 Q2 | 5.41 Billion INR | 0.0% |
| 2022 FY | 5.85 Billion INR | 7.86% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q4 | 5.85 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2021 Q2 | 5.81 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 FY | 5.42 Billion INR | 0.87% |
| 2021 Q4 | 5.42 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q2 | 5.67 Billion INR | 0.0% |
| 2020 FY | 5.38 Billion INR | 3.32% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q4 | 5.38 Billion INR | 0.0% |
| 2019 Q4 | 5.21 Billion INR | 0.0% |
| 2019 FY | 5.21 Billion INR | 20.87% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q2 | 4.7 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2018 FY | 4.31 Billion INR | -16.03% |
| 2018 Q4 | 4.31 Billion INR | 0.0% |
| 2018 Q1 | - INR | 0.0% |
| 2017 FY | 5.13 Billion INR | 51.0% |
| 2016 Q3 | 3.64 Billion INR | 3.44% |
| 2016 Q1 | - INR | 0.0% |
| 2016 Q2 | 3.52 Billion INR | 0.0% |
| 2016 FY | 3.39 Billion INR | 7.27% |
| 2016 Q4 | 3.39 Billion INR | -6.76% |
| 2015 FY | 3.16 Billion INR | -9.43% |
| 2014 FY | 3.49 Billion INR | -2.6% |
| 2013 FY | 3.59 Billion INR | 10.48% |
| 2012 FY | 3.25 Billion INR | -6.91% |
| 2011 FY | 3.49 Billion INR | -1.32% |
| 2010 FY | 3.53 Billion INR | 7.47% |
| 2009 FY | 3.29 Billion INR | 10.61% |
| 2008 FY | 2.97 Billion INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 16.27 Billion INR | 66.212% |
| Aurobindo Pharma Limited | 152.2 Billion INR | 96.387% |
| Glenmark Life Sciences Limited | 5.18 Billion INR | -6.131% |
| Granules India Limited | 22.95 Billion INR | 76.046% |
| Indoco Remedies Limited | 10.34 Billion INR | 46.834% |
| Achyut Healthcare Limited | 2.01 Million INR | -273052.608% |
| Ajanta Pharma Limited | 10.71 Billion INR | 48.661% |
| Alkem Laboratories Limited | 48.6 Billion INR | 88.687% |
| Alpa Laboratories Limited | 307.12 Million INR | -1690.351% |
| Brooks Laboratories Limited | 248.6 Million INR | -2111.802% |
| AstraZeneca Pharma India Limited | 3.66 Billion INR | -50.188% |
| Bajaj HealthCare Limited | 4.86 Billion INR | -12.961% |
| Bliss GVS Pharma Limited | 2.1 Billion INR | -160.737% |
| Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 94.86% |
| Eris Lifesciences Limited | 38.26 Billion INR | 85.631% |
| FDC Limited | 3.7 Billion INR | -48.241% |
| Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 91.555% |
| Gufic Biosciences Limited | 5.59 Billion INR | 1.808% |
| Ind-Swift Laboratories Limited | 2.28 Billion INR | -140.168% |
| Ipca Laboratories Limited | 33.74 Billion INR | 83.704% |
| Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -1752.865% |
| Krebs Biochemicals & Industries Limited | 2.97 Billion INR | -84.893% |
| Lasa Supergenerics Limited | 541.92 Million INR | -914.635% |
| Laurus Labs Limited | 42.71 Billion INR | 87.127% |
| Lupin Limited | 96.23 Billion INR | 94.286% |
| Mankind Pharma Limited | 23.87 Billion INR | 76.969% |
| Medicamen Biotech Limited | 940.36 Million INR | -484.725% |
| Medico Remedies Limited | 438.24 Million INR | -1154.68% |
| Megasoft Limited | 1.85 Billion INR | -196.715% |
| NATCO Pharma Limited | 10.53 Billion INR | 47.792% |
| Piramal Pharma Limited | 74 Billion INR | 92.57% |
| RPG Life Sciences Limited | 1.38 Billion INR | -298.389% |
| Sigachi Industries Limited | 2.53 Billion INR | -117.226% |
| Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 97.005% |
| Suven Pharmaceuticals Limited | 2.03 Billion INR | -170.302% |
| Syncom Formulations (India) Limited | 1.16 Billion INR | -371.894% |
| Unichem Laboratories Limited | 8.06 Billion INR | 31.858% |
| Wanbury Limited | 3.15 Billion INR | -74.252% |
| Windlas Biotech Limited | 1.76 Billion INR | -211.94% |
| ZIM Laboratories Limited | 2.08 Billion INR | -164.257% |
| Zydus Lifesciences Limited | 71.79 Billion INR | 92.341% |
| Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | -41.246% |
| Divi's Laboratories Limited | 18.99 Billion INR | 71.045% |
| Hester Biosciences Limited | 3.59 Billion INR | -52.962% |
| Procter & Gamble Health Limited | 2.56 Billion INR | -114.687% |
| Amrutanjan Health Care Limited | 783.82 Million INR | -601.505% |
| Bal Pharma Limited | 2.51 Billion INR | -118.955% |
| Strides Pharma Science Limited | 37.68 Billion INR | 85.407% |
| Venus Remedies Limited | 1.39 Billion INR | -294.785% |
| Aarti Pharmalabs Limited | 8.25 Billion INR | 33.356% |
| Nectar Lifesciences Limited | 11.21 Billion INR | 50.985% |
| Shilpa Medicare Limited | 12.93 Billion INR | 57.483% |
| Aarti Drugs Limited | 11.5 Billion INR | 52.203% |
| IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | 13.12% |
| Suven Life Sciences Limited | 148.62 Million INR | -3599.721% |
| Ind-Swift Limited | 13.45 Billion INR | 59.128% |
| Valiant Laboratories Limited | 1.05 Billion INR | -419.586% |
| J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | 48.65% |
| Solara Active Pharma Sciences Limited | 14.14 Billion INR | 61.124% |
| Themis Medicare Limited | 1.88 Billion INR | -191.313% |
| Hikal Limited | 12.99 Billion INR | 57.687% |
| Torrent Pharmaceuticals Limited | 82.05 Billion INR | 93.299% |
| Sequent Scientific Limited | 8.27 Billion INR | 33.546% |
| Novartis India Limited | 1.8 Billion INR | -205.289% |
| Wockhardt Limited | 39.87 Billion INR | 86.209% |
| Jubilant Pharmova Limited | 61.27 Billion INR | 91.026% |
| Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -1803.941% |
| Morepen Laboratories Limited | 4.45 Billion INR | -23.292% |
| Kilitch Drugs (India) Limited | 643.88 Million INR | -753.969% |
| Mangalam Drugs & Organics Limited | 1.97 Billion INR | -178.224% |